drugset / Trial / NCT00767507

Maintenance of Platelet Inhibition With Cangrelor

NCT00767507

Phase 2 Completed 221 enrolled The Medicines Company
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to demonstrate that patients receiving cangrelor infusion before coronary artery bypass grafting have an acceptable safety profile and can undergo surgery without excessive bleeding peri-operatively.

Timeline

Start
2008-10
Primary completion
2011-06
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cangrelor Small molecule 0.75 ug/kg Intravenous